Mohamed M. Hegazi, M.D.

Mohamed M. Hegazi, M.D.

Mohamed M. Hegazi, M.D.

UofL Health - Brown Cancer Center
529 South Jackson Street
Louisville, KY 40202
502-562-3367- Academic Office
502-562-4543 - Patient Appointments

Clinical Expertise
Blood and Bone Marrow Transplantation; Oncology; Hematology

Board Certifications

  • American Board of Internal Medicine -
    Internal Medicine / Medical Oncology / Hematology

Education and Training

  • Medical School: University of Mansoura Faculty of Medicine
  • Residency: Jersey Shore University Medical Center
  • Fellowship: University of Louisville

Get To Know Dr. Hegazi

Featured Publications

  • Kumar J, Al-Kawaaz M, Martin BA, Hegazi MM, Tan B, Gratzinger D. Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma. Am J Clin Pathol. 2022 Oct 6;158(4):449-455. doi: 10.1093/ajcp/aqac087. PMID: 35964234.
  • Maharaj S, Murray D, Hegazi M, Chang S. Breast Implant-Associated CD30 Negative Peripheral T-Cell Lymphoma, NOS. Hemasphere. 2020 Dec 9;5(1):e507. doi: 10.1097/HS9.0000000000000507. PMID: 33324953; PMCID: PMC7732339.
  • Hashmi H, Bhandari S, Kumar R, Tripathi P, Rhodes JB, Figg L, Baize T, Krem MM, Hegazi M, Emmons R. Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis. Hematol Oncol Stem Cell Ther. 2020 Dec;13(4):232-237. doi: 10.1016/j.hemonc.2020.03.002. Epub 2020 May 8. PMID: 32413417.
  • Hashmi H, Bhandari S, Dhanoa J, Wu X, Rai S, Figg L, Baize T, Krem M, Hegazi M, Emmons R. Clinical Outcomes Using Mycophenolate and Tacrolimus for Graft-versus-Host Disease Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplant: A Single Institution Experience. Cureus. 2020 Feb 5;12(2):e6893. doi: 10.7759/cureus.6893. PMID: 32190456; PMCID: PMC7058400.